Johnson & Johnson (JNJ) Q3 2026 Earnings Call: Sales Guidance Raised
Source Tradingkey
Key Takeaways
- Johnson & Johnson reported Q3 2026 worldwide sales of $25.4 billion, up 6.0% operationally. U.S. sales increased 9.1%, while sales outside the U.S. rose 1.8%.
- Innovative Medicine sales grew 7.9% to $16.8 billion, supported by oncology growth of approximately 17% and strong demand for TREMFYA, CAPLYTA, SPRAVATO and RYBREVANT plus LAZCLUZE.
- MedTech sales increased 2.5% to $8.6 billion. Shockwave grew 17.2%, but Abiomed declined 1.5% and Surgery fell 1.0% amid international headwinds.
- GAAP net earnings were $210 million, or $0.09 per diluted share, reflecting the proposed talc litigation resolution and transaction-related expenses. Adjusted EPS declined 7.5% to $2.59.
- Management raised and narrowed 2026 operational sales growth guidance to 6.7%-7.1%, with operational sales of $100.7 billion at the midpoint.
- The company expects its existing portfolio, new launches and internal strategic investments to support double-digit growth by the end of the decade. Management clarified that this objective does not assume additional M&A.
Key Financial Results
| Metric | Q3 2026 | Change / Commentary |
|---|---|---|
| Worldwide sales | $25.4 billion | Up 6.0% operationally |
| U.S. sales growth | — | 9.1% |
| International sales growth | — | 1.8% |
| Innovative Medicine sales | $16.8 billion | Up 7.9% |
| MedTech sales | $8.6 billion | Up 2.5% |
| GAAP net earnings | $210 million | Impacted by talc litigation and transaction expenses |
| GAAP diluted EPS | $0.09 | Down from $2.12 in Q3 2025 |
| Adjusted net earnings | $6.3 billion | Down 6.8% |
| Adjusted diluted EPS | $2.59 | Down 7.5% |
| R&D spending | Approximately $4.7 billion | 18.3% of sales; includes $1 billion related to Firefly Bio |
| Free cash flow | More than $6 billion | Full-year guidance remains approximately $21 billion |
| Cash and marketable securities | Approximately $17 billion | At quarter-end |
| Debt | Approximately $45 billion | Net debt of approximately $28 billion |
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
AI debt fears weigh on the Nasdaq as Brent crude climbs back above US$100. Explore the week's key market moves, rising risks and what Australian investors should watch next.
Chip stocks have closed lower for eight straight sessions, their longest losing streak in 16 years, according to Barchart. The iShares Semiconductor ETF (SOXX) closed Thursday at $514.71, nearly 14% o
Elon Musk showed off a flying Tesla Roadster at SpaceX’s McGregor test site in Texas on Thursday. “Turns out the future does have flying cars,” the Tesla CEO posted on X afterward.Yet the flight syste
Bitcoin momentum turned positive on two widely watched indicators this week, ending a bearish stretch of roughly 10 months. PlanB, creator of the stock-to-flow model, shared the flip and questioned wh
Apple’s iPhone Duo pre-orders sold out within minutes on October 16, and online orders for the $1,999 foldable no longer arrive before Christmas.That leaves holiday shoppers with fewer options. Apple’
